tiprankstipranks
Lifecore Biomedical (LFCR)
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Forecast & Price Target

102 Followers
See the Price Targets and Ratings of:

LFCR Analyst Ratings

Hold
1Ratings
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Lifecore
Biomedical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LFCR Stock 12 Month Forecast

Average Price Target

$6.00
▲(0.33% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Lifecore Biomedical in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 0.33% change from the last price of $5.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","11":"$11","4.25":"$4.25","6.5":"$6.5","8.75":"$8.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.25,6.5,8.75,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Jul<br/>2023","9":"Oct<br/>2023","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.39,6.359999999999999,6.33,6.3,6.27,6.24,6.21,6.18,6.1499999999999995,6.12,6.09,6.06,6.03,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.39,6.359999999999999,6.33,6.3,6.27,6.24,6.21,6.18,6.1499999999999995,6.12,6.09,6.06,6.03,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.39,6.359999999999999,6.33,6.3,6.27,6.24,6.21,6.18,6.1499999999999995,6.12,6.09,6.06,6.03,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.28,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.68,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.78,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.24,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.64,"date":1684454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.46,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.87,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.23,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.39,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.00Average Price Target$6.00Lowest Price Target$6.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington
$10.00
Buy
67.22%
Upside
Reiterated
09/01/23
Lifecore price target lowered to $10 from $11 at BarringtonLifecore price target lowered to $10 from $11 at Barrington

Best Analysts Covering Lifecore Biomedical

Which Analyst Should I Follow If I Want to Buy LFCR and Sell After:
1 Month
Michael PetuskyBarrington
Success Rate
6/15 ratings generated profit
40%
Average Return
+0.44%
reiterated a buy rating 9 months ago
Copying Michael Petusky's trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +0.44% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Michael PetuskyBarrington
Success Rate
3/15 ratings generated profit
20%
Average Return
>-0.01%
reiterated a buy rating 9 months ago
Copying Michael Petusky's trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of >-0.01% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Michael PetuskyBarrington
Success Rate
2/15 ratings generated profit
13%
Average Return
-7.14%
reiterated a buy rating 9 months ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -7.14% per trade.
2 Years
Michael PetuskyBarrington
Success Rate
2/15 ratings generated profit
13%
Average Return
-11.07%
reiterated a buy rating 9 months ago
Copying Michael Petusky's trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -11.07% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LFCR Analyst Recommendation Trends

Rating
Mar 23
May 23
Jun 23
Sep 23
Apr 24
Strong Buy
2
2
2
0
0
Buy
2
2
2
3
2
Hold
1
1
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
5
4
4
In the current month, LFCR has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. LFCR average Analyst price target in the past 3 months is $6.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

LFCR Financial Forecast

LFCR Earnings Forecast

Next quarter’s earnings estimate for LFCR is -$0.10 with a range of -$0.10 to -$0.10. The previous quarter’s EPS was -$0.06. LFCR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year LFCR has Underperformed its overall industry.
Next quarter’s earnings estimate for LFCR is -$0.10 with a range of -$0.10 to -$0.10. The previous quarter’s EPS was -$0.06. LFCR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year LFCR has Underperformed its overall industry.

LFCR Sales Forecast

Next quarter’s sales forecast for LFCR is $34.87M with a range of $34.87M to $34.87M. The previous quarter’s sales results were ―. LFCR beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.22% of the time in the same period. In the last calendar year LFCR has Outperformed its overall industry.
Next quarter’s sales forecast for LFCR is $34.87M with a range of $34.87M to $34.87M. The previous quarter’s sales results were ―. LFCR beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.22% of the time in the same period. In the last calendar year LFCR has Outperformed its overall industry.

LFCR Stock Forecast FAQ

What is LFCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Lifecore Biomedical’s 12-month average price target is $6.00.
    What is LFCR’s upside potential, based on the analysts’ average price target?
    Lifecore Biomedical has 0.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LFCR a Buy, Sell or Hold?
          Lifecore Biomedical has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Lifecore Biomedical’s price target?
            The average price target for Lifecore Biomedical is $6.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.00 ,the lowest forecast is $6.00. The average price target represents 0.33% Increase from the current price of $5.98.
              What do analysts say about Lifecore Biomedical?
              Lifecore Biomedical’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of LFCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis